Search results
Results from the WOW.Com Content Network
A formal survey of dextromethorphan users [25] showed that more than half of users reported experience of these withdrawal symptoms individually for the first week after long-term/addictive dextromethorphan use: fatigue, apathy, flashbacks, and constipation. Over a quarter reported insomnia, nightmares, anhedonia, impaired memory, attention ...
Dextromethorphan, sold under the brand name Robitussin among others, is a cough suppressant used in many cough and cold medicines. [6] In 2022, the US Food and Drug Administration (FDA) approved the combination dextromethorphan/bupropion to serve as a rapid-acting antidepressant in people with major depressive disorder.
Dextromethorphan/bupropion (DXM/BUP), sold under the brand name Auvelity, is a combination medication for the treatment of major depressive disorder (MDD). [1] Its active components are dextromethorphan (DXM) and bupropion . [ 1 ]
Ketamine’s antidepressant effects are part of what prompted researchers to explore other drugs that target glutamate—like the venerable cough suppressant dextromethorphan found in Robitussin ...
The provider of a dextromethorphan containing product must acquire proof of age if they believe that the potential purchaser is below the age of 18. Any person found to possess more than one gram of pure dextromethorphan without the required credentials is subject to a $1000 fine for the first offense and a $2500 fine for each subsequent offense.
Antitussives, or cough suppressants, are substances which suppress the coughing itself. Examples are dextromethorphan, benzonatate, codeine, hydrocodone, pholcodine, noscapine, cloperastine, and butamirate. Antihistamines, for allergic rhinitis, may produce mild sedation and reduce other associated symptoms, like a runny nose and watery eyes.
Dextromethorphan/quinidine is a combination of these two generic drugs, and is the first FDA-approved drug for the treatment of PBA, approved on October 29, 2010. [ 50 ] In the pivotal multicenter study that led to its approval, the "Objectives...[were] to evaluate the safety, tolerability, and efficacy of two different doses of AVP-923 ...
Quinidine prevents the metabolism of dextromethorphan into its active metabolite dextrorphan, which is a much more potent NMDA receptor antagonist but much less potent serotonin reuptake inhibitor than dextromethorphan. [6] [3] The mechanism of action of dextromethorphan/quinidine in the treatment of PBA is unknown. [3]